Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location.

JNCI Cancer Spectr · 2020 · PMC7477374 · PMID 32923935

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Prior studies found a nearly 20% reduced risk among ever HT users irrespective of BRAF and KRAS mutation status, although effect estimates did not reach statistical significance ( 22 , 23 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.